BMRN
Biomarin Pharmaceutical Inc
62.20$
-1.8%
vs. previous close
Closing price · As of: Sep 23, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 16.3% | 17.1% | 18.8% | 18.4% | 21.1% | 21.1% | 28.2% | 25.5% | 24.0% | 22.0% | 20.3% | 22.9% | |
| 83.7% | 82.9% | 81.2% | 81.6% | 78.9% | 78.9% | 71.8% | 74.5% | 76.0% | 78.0% | 79.7% | 77.1% | |
| 61.6% | 71.3% | 59.3% | 46.5% | 46.7% | 42.0% | 33.8% | 34.1% | 31.0% | 30.9% | 26.2% | 28.6% | |
| 40.3% | 45.2% | 42.7% | 42.2% | 18.8% | 17.5% | 18.0% | 19.2% | 17.8% | 16.7% | 18.7% | 35.8% | |
| 96.1% | 95.4% | 153.2% | 82.7% | 87.1% | 84.8% | 74.2% | 79.0% | 68.3% | 70.3% | 62.7% | 60.6% | |
| -12.4% | -12.4% | -71.9% | -1.1% | -8.3% | -5.9% | -2.3% | -4.5% | 7.7% | 7.7% | 17.0% | 16.6% | |
| 4.9% | 4.3% | 3.5% | 3.3% | 2.9% | 1.4% | 1.6% | 0.8% | 0.8% | 0.7% | 0.4% | 0.3% | |
| -16.7% | -17.4% | -74.4% | -2.7% | -9.6% | -5.6% | -2.6% | -4.1% | 7.1% | 7.8% | 19.0% | 15.0% | |
| 1.2% | 1.9% | -18.0% | 6.2% | -4.4% | -4.2% | -48.5% | -0.6% | 0.4% | 0.9% | 4.0% | 4.1% | |
| -17.9% | -19.3% | -56.4% | -8.9% | -5.2% | -1.4% | 45.9% | -3.5% | 6.8% | 6.9% | 15.0% | 10.8% | |
| -6.1% | -8.2% | -62.5% | 6.9% | -0.2% | 1.9% | 4.5% | 2.6% | 12.7% | 12.7% | 22.8% | 17.8% |
Data as of: September 23, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.